BNET Industries
Merck & Co. Inc. (MRK) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $24.1B
- Profit
- Dec 31 2007
- $3.2B
- Market Cap
- Aug 27 2008
- $76.5B
Latest News and Analysis
Merck's Charm Offensive for Gardasil
Mike Huckman submits: In the current monster-sized issue of Vogue, my producer, Ruth, while killing time on the Delta shuttle on our way from New York to Boston for a shoot this week, uncovered a blogworthy story buried in the hundreds and hundreds and hundreds of pages of fashion...
Dow Price Targets from Last November
Hickey and Walters Bespoke submit: Barry Ritholtz over at the Big Picture recently highlighted Bloomberg's Chart of the Day showing that analyst profit forecasts are currently worse than ever. With that in mind, we pulled up a post we did back in November highlighting the average analyst price...
Merck?s Gardasil: A Risky and Unnecessary Vaccine
Wall Street Weather submits: “Merck lobbied every opinion leader, women’s group, medical society, politicians, and went directly to the people – it created a sense of panic that says you have to have this vaccine now.”- Dr. Diane Harper, professor of medicine at Dartmouth Medical School and a principal investigator...
Why I'm Buying Amylin Now
Trader Mark submits: I'm following the "buy the busted stocks" instead of breakouts methodology, but breaking a rule on buying individual biotech stocks with today's purchase of Amylin Pharmaceuticals AMLN. This is one of the few biotechs I know pretty well, and have followed for quite a while - mostly...
Merck Vioxx Study Was For Marketing: Researchers
LONDON (Reuters) - A 1999 clinical study that Merck & Co Inc MRK said was done to test side effects of its now-withdrawn painkiller Vioxx was done primarily to support a marketing campaign before its launch, according to researchers. The real aim of...
Looking Inside the New Ben Graham ETN Baskets
Rick Konrad submits: Exchange traded notes [ETN] are a fairly new investment product that share some characteristics of exchange-traded funds, or ETFs. They are simply direct debt obligations issued by a bank or investment firm rather than an interest in a pool of securities that define an ETF.A bank...
Time to Invest in Pharmaceuticals?
Howard Sun submits: The prices of many pharmaceutical companies have been beaten down by Wall Street in recent months. With companies like Pfizer PFE, Schering-Plough SGP and Bristol-Myers Squibb BMY reaching lower lows, one has to wonder when the pain will end as these companies are now significantly undervalued. The...
5 Potential Buyout Targets in Biotech - Barron's
Bristol-Myers Squibb BMY made a $4.5B bid for the shares of ImClone IMCL it doesn't already own. Roche Holdings (RHHBY.PK) made a $44B offer for the shares of Genetech DNA it doesn't own. Both targets want the bid prices raised. Barron's Lawrence Strauss says these are just the two latest...
How Have 'Traditional Defensive Stocks' Done in This Downturn?
Larry Bellehumeur submits: Like many people on Seeking Alpha, I tend to watch a lot of Business-related programming on Bloomberg and BNN Canada. Over the past few months, more and more Analysts and Fund Managers are telling the viewers to “get more defensive” in their portfolio. When asked which...
Dow 30 Trading Ranges
Below we highlight the 30 Dow members with respect to their various trading ranges. After the recent volatility in the markets (S&P 500 +2.9% on Tuesday, -1.8% yesterday) some of these stocks are on the move. BAC had traded at its theoretical high of $34 and has declined over the...
$120 Oil's Struggle with the Dow Industrials
Steven Hansen submits: Is this round two of the price of oil on the Dow Industrials? Will the effects on the Dow of the 1973 Oil Crisis repeat itself? There are several similarities and differences. One similarity, which got me thinking, was that the percentage increase in oil prices was...
The Case Against Investing in the Dow Industrials (For Now)
Steven Hansen submits: There appears to be 16 year Dow growth investing cycles followed by 16 years of volatility. The 16 year period of volatility began in 1999, and on a historical basis would end in 2015. The following Dow Jones Industrial Average charts illustrate this...
China Biotech in Review: Company Profiles and Drug Advancement
ChinaBio Today submits: In ChinaBio Today, we profiled two China biotechs last week. One, Shenogen Pharma Group, recently won one of the two “Most Promising Company” awards at the ChinaBio Investor Forum, held in early July in Shanghai see story. Shenogen combines facets of Western and Eastern pharmaceutical practices....
FDA Unexpectedly Rejects Schering Anesthesia Drug
By Ransdell Pierson NEW YORK (Reuters) - Schering-Plough Corp said SGP on Friday U.S. regulators had rejected Bridion, its drug to reverse the effects of anesthesia that had been heralded as a breakthrough product by analysts and was unanimously recommended by...
Cash is King: The Search for Recession Proof Stocks
Andrew Snyder submits: The equities market reminds me of a girl I used to date. Her mood could change faster than an afternoon breeze. One minute the world was grand, the next she was spewing fire from her nostrils and chasing me with a pitchfork. Fortunately, there were...
PowerShares FTSE RAFI Healthcare: Big Bets on Dow Dogs
Don Dion submits: While the PowerShares FTSE RAFI Health Care fund PRFH has experienced a recent leap in momentum, this move may not come as a surprise to many health care investors. PRFH has jumped 20 spots, from 61 to 41, on our PowerShares Momentum Tracker Sector Momentum...
Pharma Outsourcing: Industry Can't Win for Losing
Given all the trauma the drug industry is currently going through, you can hardly blame executives for cutting costs wherever they can. Unsurprisingly, outsourcing is a big part of Big Pharma's repair toolkit these days. Pfizer, for instance, says that 17 percent of its manufacturing and active ingredients are currently...
Merck & Co., Inc. Q2 2008 Earnings Call Transcript
Merck & Co., Inc. MRK Q2 FY08 Earnings Call
Schering-Plough Now in the Feds' Crosshairs
Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
Is Merck Hanging Schering Out to Dry on Vytorin?
Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Next »
- page 1 of 95
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- stock (112 results)
- vaccine (80 results)
- FDA (77 results)
- Hackensack (70 results)
- Pfizer Inc. (63 results)
- collaboration (50 results)
- Sales (47 results)
- Pharmaceutical Company (46 results)
- agreement (43 results)
- Vioxx (41 results)
- blog (28 results)
- Patient (28 results)
- health care (27 results)
- Schering-Plough Corp. (27 results)
- Bristol-Myers Squibb Co. (24 results)
- earnings per share (24 results)
- company (22 results)
- Serono S.A. (21 results)
- Marketing (20 results)
- Biotechnology (20 results)
- Industry (19 results)
- Wyeth (19 results)
- New York Stock Exchange (18 results)
- GlaxoSmithKline Plc. (18 results)
- Johnson & Johnson (18 results)
- Merrill Lynch & Co. Inc. (17 results)
- Sharp Corp. (17 results)
- dividend (17 results)
- Home Depot Inc. (16 results)
- earnings (15 results)
- board (15 results)
- advertisement (15 results)
- board of directors (15 results)
- analysis (14 results)
- life science (14 results)
- class action (14 results)
- Hewlett-Packard Co. (13 results)
- R&D (13 results)
- manufacturing (13 results)
- Motorola Inc. (13 results)
- financial (13 results)
- Eli Lilly & Co. (13 results)
- Novartis AG (13 results)
- acquisition (12 results)
- Zocor (12 results)
- David P. Hamilton (12 results)
- Seeking Alpha (11 results)
- Web (11 results)
- license agreement (11 results)
- job (11 results)
- Incorporated: 1927
- CEO: Mr. Richard T. Clark
Merck & Co. is a pharmaceutical company engaged in discovering, developing, producing and marketing products designed to improve human and animal health, directly and through joint ventures. Co.'s products include therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Among these are Singulair (montelukast sodium), a leukotriene receptor antagonist for the chronic treatment of asthma and for the relief of symptoms of allergic rhinitis; Cozaar (losartan potassium), Hyzaar (losartan potassium and hydrochlorothiazide); Fosamax (alendronate sodium) and Fosamax Plus D (alendronate sodium/cholecalciferol).
Key Competitors
Merck & Co. Inc. Company Info
Board of Directors
Mr. Richard T. Clark
Chairman
Ms. Anne M. Tatlock
Dr. Samuel O. Thier M.D.
Mr. Wendell P. Weeks
Mr. Peter C. Wendell
Mr. Leslie A. Brun
Dr. Johnnetta B. Cole Ph.D.
Mr. Thomas H. Glocer
Mr. Steven F. Goldstone
Mr. William B. Harrison Jr.
Dr. Harry R. Jacobson
Dr. William N. Kelley
Ms. Rochelle B. Lazarus
Dr. Thomas E. Shenk Ph.D.
Contact Information
One Merck Drive
P.O. Box 100
Whitehouse Station, NJ
908 423-1000
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
